drugset / Trial / NCT04388904

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)

NCT04388904

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART) for 12 or more weeks.

Timeline

Start
2021-09-01
Primary completion
2024-04-05
Completion
2024-04-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobicistat Small molecule 150 mg Oral
Subject Darunavir Small molecule 800 mg Oral
Subject emtricitabine Other / unclassified 200 mg Oral
Subject tenofovir alafenamide Small molecule 10 mg Oral